Figure 2

Basal levels of pSTAT1-Y701 in PBMC subsets from HDI treated responders and non-responders. Changes in basal response levels of pSTAT1 before (pre-) and after (post-) the 4 week induction phase with HDI were compared in Lymphocytes, CD4 and CD8 T cells, and CD19 B cells in HDI treated A) responding and B) non-responding melanoma patients. Two-sided paired Wilcoxon-Mann-Whitney tests were performed on melanoma patient's pre- and corresponding post- PBMCs. Adjusted P-values < 0.05 were considered significant.